Who are we ?

NeurATRIS, translational research infrastructure for innovative neuroscience therapies.


An infrastructure unique in Europe
NeurATRIS, coordinated by CEA, is a national research infrastructure to accelerate the translation of discoveries in basic research into medical innovations for the treatment of neurodegenerative and neurodevelopmental diseases.

Created in 2012 following the « Investissements d’Avenir » call for projects "Biology and Health Infrastructure", its objective is to offer a continuum of translational expertises ranging from in vitro cellular models to phase II clinical trials on patients suffering from major brain diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Multiple Sclerosis (MS) or certain brain development disorders.

Organized as a one-stop network, NeurATRIS is designed to co-ordinate research activities and technological development serving the scientific and industrial communities. It simplifies the access and the use of high level platforms (see « Platforms of NeurATRIS ») and facilitates the participation of French players in European initiatives. It also improve the attractiveness and visibility of France in the field of translational neuroscience research.

An infrastructure based on scientific excellence in neuroscience and neurology
NeurATRIS brings together 7 hospitals and public research institutes whose expertise and skills in neuroimaging, pharmacology and biotherapies are complementary and internationally recognized:

 

• ➜ CEA Paris-Saclay – MIRCen and SHFJ, in Fontenay-aux-Roses (Hauts-de-Seine, 92)
• ➜ Pitié-Salpêtrière Hospital – ICM, in Paris
• ➜ Henri Mondor Hospital – UPEC, in Créteil (Val de Marne, 94)
• ➜ Bicêtre Hospital – N-BIPS, in Kremlin Bicêtre (Val de Marne, 94)
• ➜ Évry University – I-Stem, in Evry (Essonne, 91)
• ➜ Oniris Nantes – INRAE, in Nantes (Loire-Atlantique, 44)
• ➜ Robert-Debré Hospital – NeuroDiderot, in Paris

This synergy fully meets the needs of discovery, characterisation and validation of therapeutic targets, as well as the identification of new biomarkers. It also enables the establishment of collaborations with academic and private partners by providing state-of-the-art services based on a range of technological, scientific, methodological and strategic expertise that is essential in the value chain of translational neuroscience research activities.